Key facts
- Branch Therapeutics’s last known valuation is $14.0M (May 2025).
- It has raised $4.0M across 1 recorded rounds; the latest was Seed Round ($4.0M) in Apr 2025.
- Notable investors include GKCC, LLC, Tech Launch Arizona, Translational Therapeutics Accelerator.
- Branch Therapeutics has filed 1 Form D with the SEC, most recently May 2025 ($4.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Branch Therapeutics
Funding rounds
1 roundsAbout Branch Therapeutics
Developer of a cancer drug designed for colorectal cancer treatment. The company focuses on targeting key drivers of cancer with multi-targeted kinase inhibitors, driving the initiation and progression of nearly all colorectal cancers, enabling patients to overcome cancer progression and drug resistance.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2024
- Ownership
- Privately Held (backing)
Branch Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Branch Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Branch Therapeutics in its N-PORT filings yet. We sweep new filings monthly.